Combination chemotherapy in advanced adenocarcinoma of the fallopian tube

Muntz, H. G.; Tarraza, Hm; Goff, Ba; Granai, C O.; Rice, Lw; Nikrui, Najmosama; Af, Fuller

doi:10.1016/0020-7292(92)90361-l

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the overall response rate observed was 70%, with a median duration of response of 12.5 months (range, 3-52 months), results that are highly comparable to those obtained in the treatment of patients with ovarian carcinoma and that confirm previous reports on smaller numbers of evaluable patients. [31][32][33][34][35][36] The high response rate observed in the eight evaluable patients who were treated with a combination of carboplatin and paclitaxel prompts us to suggest that, parallel to the situation in patients with ovarian carcinoma, 37 a combination of a platinum compound and paclitaxel should be regarded as the chemotherapy standard in the treatment of patients with fallopian tube carcinoma. Our data also confirm that, in patients who have elevated prechemotherapy serum CA-125 levels, this marker can safely be used as a surrogate marker for response and progression.…”

Section: Discussionmentioning

confidence: 99%

Carcinoma of the fallopian tube

Baekelandt¹,

Nesbakken²,

Kristensen³

et al. 2000

Cancer

152

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Carcinoma of the fallopian tube

Baekelandt¹,

Nesbakken²,

Kristensen³

et al. 2000

Cancer

152

View full text Add to dashboard Cite

“…Treatment typically begins with surgical cytoreduction followed by adjuvant chemotherapy for women with advanced stage disease 7. Several reports have suggested that tubal carcinomas respond well to platinum‐based chemotherapy 31–35. Although no prospective trials have specifically examined tubal carcinomas, these patients have often been included in prospective, cooperative group trials for women with ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Improved survival for fallopian tube cancer

Wethington

Herzog

Seshan

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. Fallopian tube cancers are rare neoplasms. These malignancies are thought to behave biologically and clinically like ovarian cancer. The purpose of this study was to compare the clinical behavior and outcome of fallopian tube and ovarian cancer. METHODS. The Surveillance, Epidemiology, and End Results database was reviewed to identify women with tumors of the fallopian tube (FT) and ovary (OV) diagnosed between 1988 and 2004. Demographic and clinical data were compared, and the impact of tumor site on survival was analyzed using Cox models and the Kaplan‐Meier method. RESULTS. A total of 55,825 patients were identified, 1576 (3%) with FT and 54,249 (97%) with OV cancer. FT patients were more likely to present with early stage tumors (P < .001). Among FT patients, 47% had stage I/II tumors compared with 29% of OV cancers. In an adjusted Cox model of all patients, cancer‐specific mortality was 48% lower in FT patients (hazard ratio, 0.52; 95% confidence interval [CI], 0.48‐0.56) compared with OV cancer. Among patients with FT tumors, advanced age and stage were independent predictors of decreased survival. When stratified by stage, survival was similar for stage I and II tumors, but stage III and IV FT patients had an improved survival. The 5‐year survival for stage III FT cancer was 54% (95% CI, 48%‐60%), compared with 30% (95% CI, 29%‐31%) for OV. CONCLUSIONS. Fallopian tube cancers present earlier and at advanced stage have a better overall survival than primary ovarian malignancies. Future clinical trials should recognize the possible distinct clinical behavior of fallopian tube cancers. Cancer 2008. © 2008 American Cancer Society.

show abstract

“…Other examples of response to carboplatin have also been reported. 72 Recently, Gemignani et al 73 reported the use of paclitaxel-based chemotherapy after initial surgery in 24 patients with primary fallopian tube adenocarcinoma. The overall median progression-free survival was 27 months for the entire group.…”

Section: Combination Chemotherapymentioning

confidence: 99%